Results for two new third-generation EGFR TKIs
PFS (A) and OS (B) in osimertinib and gefitinib treatment groups. *For... | Download Scientific Diagram
Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib | SpringerLink
Additional ADAURA Analyses Help Support the Benefit of Adjuvant Osimertinib in Patients With Resected EGFR-Mutated NSCLC - ILCN.org (ILCN/WCLC)
ADAURA Establishes Adjuvant Osimertinib as a New Standard of Care for Early-Stage EGFR-Mutated NSCLC
Kaplan-Meyer curves for progression free survival of osimertinib by (a)... | Download Scientific Diagram
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status - ScienceDirect
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
FLAURA trial: overall survival results confirms the efficacy of osimertinib in the treatment of NSCLC - Daily Reporter
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study | PLOS ONE
Overall survival in patients with or without chemotherapy after... | Download Scientific Diagram
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer | NEJM
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis | BMC Cancer | Full Text
Overall survival in enrolled patients treated with osimertinib... | Download Scientific Diagram
Osimertinib in Advanced Lung Cancer with EGFR Mutations - NCI
Efficacy of Resectable NSCLC – TAGRISSO® (osimertinib) Nurse Center
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR‐mutant nonsmall cell lung cancer with brain metastasis - Zhao - 2022 - International Journal of Cancer -
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study | Future Oncology
Front-line osimertinib improves overall survival in EGFR-mutation positive NSCLC
